These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22099390)

  • 1. SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study.
    Adkins DE; Khachane AN; McClay JL; Aberg K; Bukszár J; Sullivan PF; van den Oord EJ
    Schizophr Res; 2012 Mar; 135(1-3):200-1. PubMed ID: 22099390
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic variation in CYP3A43 is associated with response to antipsychotic medication.
    Brandl EJ; Chowdhury NI; Tiwari AK; Lett TA; Meltzer HY; Kennedy JL; Müller DJ
    J Neural Transm (Vienna); 2015 Jan; 122(1):29-34. PubMed ID: 25150845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.
    Giegling I; Balzarro B; Porcelli S; Schäfer M; Hartmann AM; Friedl M; Konte B; Krämer P; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Arch Psychiatry Clin Neurosci; 2013 Feb; 263(1):65-74. PubMed ID: 22893251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
    Förstl H
    Internist (Berl); 2007 Jun; 48(6):642-4. PubMed ID: 17497111
    [No Abstract]   [Full Text] [Related]  

  • 5. DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs.
    Ota VK; Spíndola LN; Gadelha A; dos Santos Filho AF; Santoro ML; Christofolini DM; Bellucco FT; Ribeiro-dos-Santos ÂK; Santos S; Mari Jde J; Melaragno MI; Bressan RA; Smith Mde A; Belangero SI
    Schizophr Res; 2012 Dec; 142(1-3):206-8. PubMed ID: 23036699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical problems in pharmacogenetic studies of psychiatric disorders.
    Serretti A; Artioli P
    Pharmacogenomics J; 2006; 6(5):289-95. PubMed ID: 16550208
    [No Abstract]   [Full Text] [Related]  

  • 7. [Too early for pharmacogenetics in psychiatric practice].
    Vinkers CH
    Tijdschr Psychiatr; 2019; 61(5):298-300. PubMed ID: 31180566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 10. Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
    Spellmann I; Rujescu D; Musil R; Meyerwas S; Giegling I; Genius J; Zill P; Dehning S; Cerovecki A; Seemüller F; Schennach R; Hartmann AM; Schäfer M; Müller N; Möller HJ; Riedel M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():190-5. PubMed ID: 24576533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
    Volpi S; Potkin SG; Malhotra AK; Licamele L; Lavedan C
    J Clin Psychiatry; 2009 Jun; 70(6):801-9. PubMed ID: 19573479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic medication in adolescents: a review.
    Rifkin A; Wortman R; Reardon G; Siris SG
    J Clin Psychiatry; 1986 Aug; 47(8):400-8. PubMed ID: 2874127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
    Need AC; Keefe RS; Ge D; Grossman I; Dickson S; McEvoy JP; Goldstein DB
    Eur J Hum Genet; 2009 Jul; 17(7):946-57. PubMed ID: 19156168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.
    Campbell DB; Ebert PJ; Skelly T; Stroup TS; Lieberman J; Levitt P; Sullivan PF
    Biol Psychiatry; 2008 Jan; 63(1):32-41. PubMed ID: 17588543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics for the individualization of psychiatric treatment.
    Arranz MJ; Collier D; Kerwin RW
    Am J Pharmacogenomics; 2001; 1(1):3-10. PubMed ID: 12173312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.
    Levine SZ; Rabinowitz J; Faries D; Lawson AH; Ascher-Svanum H
    Schizophr Res; 2012 May; 137(1-3):141-6. PubMed ID: 22316567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotic medications and the treatment of schizophrenia.
    Lewis DA
    Am J Psychiatry; 2002 Feb; 159(2):177-9. PubMed ID: 11823256
    [No Abstract]   [Full Text] [Related]  

  • 19. Applications of the AMP/AMDP-System to drug trials.
    Mod Probl Pharmacopsychiatry; 1983; 20():204-10. PubMed ID: 6137767
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
    Pae CU; Chiesa A; Serretti A
    Psychiatry Res; 2010 Jul; 178(2):430-2. PubMed ID: 20471098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.